Milk calcium pharma grade API for tablet, capsule, granule, and injectable precursor applications is a spray-dried mineral complex isolated from bovine milk, typically assayed at 20–26% w/w elemental calcium and 8–12% w/w phosphorus, with residual lactose below 0.5% w/w and loss on drying below 2.5% w/w at 105°C. The material is not a single calcium salt but a hydroxyapatite/citrate/phosphoprotein matrix, which means downstream unit operations are governed by solubility lag, pH-dependent release of calcium ions, and shear sensitivity of mineral-protein agglomerates. Oral solid dosage specifications reference USP <2040>, ICH Q3D, and Ph. Eur. 2.9.1; injectable conversion routes reference USP <85>, USP <790>, and Ph. Eur. 2.9.19 for particulate burden control. Direct intravenous administration of the intact mineral complex is not performed because primary particle size exceeds 1.0 µm; the injectable application route is confined to downstream conversion into soluble calcium salts or sterile-filtered complex solutions.

Compression of 38% w/w Milk Calcium in Rotary Tablet Presses at Main Force 25–40 kN

Direct compression of milk calcium pharma grade in chewable tablets uses the native flow and compressibility of the spray-dried matrix only within a narrow formulation band; below 25% w/w, calcium content per tablet drops below the labeled dosage when total tablet mass is capped at 1,100 mg, and above 42% w/w, ejection force rises above 1,800 N on 16-station rotary presses fitted with BN tooling, generating capping at precompression force below 8 kN. The formulation is typically loaded at 28–38% w/w with 0.5% w/w colloidal silicon dioxide and 1.25% w/w sodium stearyl fumarate; magnesium stearate is minimized to 0.8% w/w because the calcium complex exhibits retardation of dissolution when shear-induced hydrophobization of the mineral surface occurs beyond 15 min of final blending. Process parameters on 12.7 mm round flat-faced bevel-edge punch sets include main compression force of 25–40 kN, precompression force of 4–8 kN, turret speed of 35–55 rpm, and hopper shoe fill depth of 11–14 mm. Compliance is driven by USP <2040> for disintegration of dietary supplement tablets, with an accepted disintegration time of ≤ 30 min in 0.1 N HCl at 37°C, and USP <905> for uniformity of dosage units; ICH Q3D limits for lead and cadmium are applied to the starting mineral complex because milk-derived calcium can carry heavy metals when bovine intake is not controlled. Terminal product types include chewable calcium tablets at 500 mg elemental calcium per tablet, low-sodium chewable formulations for hypertensive patients, and veterinary mineral boluses where the same granulate is compressed at 20–50 kN on high-speed presses.

In hard capsule manufacturing, milk calcium pharma grade is selected when the finished dosage form must deliver calcium in combination with oil-soluble vitamins K2 and D3 without the compression phase that can destroy lipid-coated beadlets. The API is mixed with microcrystalline cellulose at 15–25% w/w, pregelatinized starch at 5–10% w/w, and vitamin D3 beadlets at 1,000 IU per capsule; milk calcium is added at 40–60% w/w of the plug mass, with the upper boundary set by plug ejectability because the mineral complex has a cohesive flow function coefficient below 4 when uncontrolled. Capsule filling on a tamping-pin machine with 5 tamping stations and fill weight target of 700 mg requires granulation via dry compaction if raw API has a Hausner ratio above 1.30; roll force is maintained at 6–9 kN/cm, screen size at 0.8 mm, and fines below 150 µm are limited to ≤ 18% to avoid powder stratification. Granule moisture is dried to 2.0–3.0% w/w and fillers are selected so that the final plug has bulk density of 0.62–0.68 g/mL and angle of repose under 34°. Compliance is anchored to USP <2040> for dietary supplement capsule disintegration, USP <905> for content uniformity of combination products, and ICH Q3D for the elemental impurity profile of the incoming mineral complex; capsule shells may be HPMC or gelatin, with HPMC preferred where water activity of the filled granule exceeds 0.45. Terminal product types include two-piece hard capsules at 333 mg elemental calcium per unit, calcium/magnesium/boron capsules for bone health, and calcium/vitamin K2/D3 capsules positioned for bone-metabolism support under regional label-claim frameworks.

How Does a Top-Spray Fluid Bed Manage the 1.5% to 2.0% Residual Moisture Ceiling in Sachet Granules?

Wet granulation of milk calcium for single-dose sachets and dry syrups is driven by the need to suspend the mineral complex in aqueous media without sedimenting into a non-redispersible cake; the formulation therefore includes a water-soluble binder phase that is incompatible with direct compression. Milk calcium is charged at 15–25% w/w of the dry granulate, with 2–4% w/w povidone K30 as binder, 10–18% w/w maltodextrin, 0.3–0.6% w/w citric acid for pH buffering, and 0.1% w/w sodium saccharin where bitter aftertaste from calcium ions is detected in sensory panel testing. The top-spray fluid bed is operated with inlet air temperature at 60–70°C, product temperature at 31–35°C, spray rate of 80–120 g/min for a 150 kg bowl, atomizing air pressure at 2.5–3.0 bar, and post-spray drying to a residual moisture of 1.5–2.0% w/w to prevent granule collapse during storage. The dried granulate is sieved to 18/40 mesh, and the 18-mesh oversize is dry-milled at 1,200 rpm with a knife mill fitted with a 0.5 mm screen; fines under 40 mesh are not recycled beyond 10% of the batch because they depress bulk density below 0.50 g/mL and increase dust generation during stick-pack filling. Compliance standards include Ph. Eur. 2.9.1 for disintegration of granules, Ph. Eur. 2.9.3 for dissolution of oral suspensions, USP <711> where modified-release granules are specified, and ICH Q6A for specification setting; pediatric formulations additionally follow the dosage form criteria in the EU Paediatric Regulation EC No 1901/2006 and require smooth mouthfeel without gritty particles above 150 µm. Terminal product types include suspension granules in 2.0–2.5 g stick packs containing 250–500 mg elemental calcium per sachet, dissolving granules for oral solutions in polypropylene bottles, and co-processed calcium/vitamin D3 granules for cold-water reconstitution in institutional feeding programs.

Effervescent delivery of calcium from milk-derived mineral complexes requires a segregated granulation step because the acid and carbonate components cannot be wet-massed in the same granulator without triggering pre-emptive carbon dioxide release. The formulation is built as a two-granule system: milk calcium pharma grade is blended with anhydrous citric acid at 18–22% w/w and sodium bicarbonate at 16–20% w/w in separate batches, with the calcium component granulated using a 5% w/w ethanolic PVP K25 solution while the bicarbonate granulate is bound with a 3% w/w prehydrolyzed starch solution. Milk calcium is incorporated at 20–30% w/w of the final tablet mass; levels above 30% w/w extend disintegration beyond 180 s in 200 mL of 20°C water because the calcium phosphate fraction generates a slow-dissolving suspension. Compaction of the final blend on a 25-station rotary press fitted with 25 mm flat-round tooling uses a main compression force of 18–28 kN, precompression at 3–5 kN, and a punch hardness specification of 14–18 kp to avoid chipping during aluminum tube packaging. The granulation area must maintain relative humidity below 20% RH and product temperature below 25°C; failure to control moisture results in spotted tablet surfaces and pre-fill pressure buildup in sealed tubes. Compliance is oriented to Ph. Eur. 2.9.1 for effervescent tablet disintegration with a limit of ≤ 180 s in 200 mL water at 20 ± 1°C, USP <2040> for supplement variants, ICH Q3D for extractable elements, and ISO 15378:2017 for primary packaging material quality. Terminal product types include effervescent calcium tablets at 500 mg elemental calcium per tablet in polypropylene tubes, powdered effervescent sachets with 4.0 g fill weight, and dual-action calcium plus vitamin C formulations in foil-laminated stick packs.

When Sterile Filtration Cannot Tolerate Particulate Loads Above Ph. Eur. 2.9.19 Limits

Injectable application of milk calcium pharma grade as an intact mineral complex is excluded from direct intravenous use because the primary particle population above 1.0 µm exceeds the sub-visible particle thresholds of Ph. Eur. 2.9.19 and USP <788>; the relevant downstream scenario is therefore conversion into soluble calcium salts or highly purified calcium complex solutions before terminal sterilization. A documented preparation route uses the API as titrated calcium source in a jacketed reactor maintained at 55–65°C, adding 2.0–2.2 kg of the mineral complex to 10 L of purified water acidified with citric acid monohydrate to pH 3.8–4.2, followed by pH adjustment to 6.8–7.2 with calcium hydroxide and filtration through a 0.45 µm polyethersulfone membrane. The resulting calcium citrate/malate solution is then sterile filtered through a 0.22 µm PVDF filter and filled into 10 mL USP Type I borosilicate glass ampoules; the calcium concentration is targeted at 0.45–0.50 mmol/mL. Published data for this specific intermediate configuration are limited, as commercial injectable calcium products rely on synthetically sourced calcium gluconate rather than milk-derived mineral feedstock; therefore process validation must follow ICH Q3D, USP <85> bacterial endotoxin testing with a limit of ≤ 2.0 EU/mL, USP <790> visible particulate testing, and 21 CFR 210/211 for sterile manufacturing. Formulation addition ratios for the upstream conversion are 17–22% w/w milk calcium relative to acid solution mass, but the final injectable formula is expressed as elemental calcium per ampoule rather than as mass percent of the original API. Terminal product types include injectable calcium citrate-malate solutions compounded in hospital pharmacies under USP <797>, small-volume parenteral calcium preparations derived from milk calcium oxide intermediates, and non-sterile oral liquid concentrates where the same filtered solution is diluted to 10 mg/mL calcium for neonatal use but is not intended for direct injection.

Medical Food Powder Fortification at Less Than 2.0% w/w Calcium to Avoid Maillard Browning

Medical food powder fortification using milk calcium pharma grade is restricted to low-dose dry blending because the residual protein-phosphopeptide fraction in the mineral complex can participate in Maillard browning when exposed to reducing sugars during warm storage. The API is added at 0.8–2.0% w/w of the powdered formula base to deliver 500–1,000 mg elemental calcium per 50 g serving without shifting the osmolality of the reconstituted liquid above 600 mOsm/kg. Downstream processing is performed in a 300 kg ribbon blender at 15 rpm for 20 min, followed by discharge through a 0.8 mm rotary sifter and packaging into foil-laminated gusseted pouches under nitrogen flush to maintain headspace oxygen below 2.0%. The blend must be protected from relative humidity above 40% RH to prevent mineral-protein lumps and to maintain the dispersibility of the spray-dried milk calcium component. Compliance is anchored to Commission Delegated Regulation (EU) 2016/128 for food for special medical purposes, FDA 21 CFR 101.9 for nutrition labeling, ISO 22000:2018 for food safety management, and ICH Q3D for elemental impurity limits carried over from the API specification. Terminal product types include adult oral nutritional supplement powders for osteoporosis dietary management, modular calcium powders in HDPE jars with desiccant closure, and low-protein medical food powder mixes where calcium-phosphorus ratio is adjusted to 1.0:1.0–1.2:1.0.